Advertisement

Neurological Sciences

, Volume 39, Issue 12, pp 2085–2089 | Cite as

Association of the rs1611115 polymorphism in DBH gene with Parkinson’s disease: a meta-analysis

  • Shan Kang
  • Mingxia Bi
  • Xixun Du
  • Qian Jiao
  • Hong Jiang
Original Article

Abstract

A meta-analysis was performed to assess the association between the dopamine beta-hydroxylase (DBH) rs1611115 genetic polymorphism and Parkinson’s disease (PD). A comprehensive search was conducted to identify all case–control or cohort studies. The fixed or random effect-pooled measure was selected on the basis of a homogeneity test among studies. Heterogeneity among studies was evaluated using the I2. We performed sensitivity analyses to evaluate the robustness of the results. Publication bias was estimated using Egger’s linear regression test. Five case–control studies corresponded to the inclusion criteria comprising 3926 patients and 3542 controls which were included in the present meta-analysis. Our meta-analysis showed no significant association between DBH rs1611115 genetic polymorphism and risk of PD in the codominant (REM, OR = 1.017, 95%CI = 0.854–1.210), dominant (REM, OR = 0.989, 95%CI = 0.826–1.185), and recessive (REM, OR = 1.007, 95%CI = 0.657–1.542) models. Moreover, in the subgroup analysis based on region (Asia and Europe), no significant associations were observed in Asia or Europe. This meta-analysis suggests that the DBH rs1611115 genetic polymorphism might not be associated with PD.

Keywords

rs1611115 DBH Polymorphism Meta-analysis Parkinson’s disease 

Notes

Funding

This work was supported by grants from the National Foundation of Natural Science of China (31471114, 31500837, and 31540075), Shandong Provincial Natural Science Foundation (BS2015SW002), Shandong Province Special Foundation for Postdoctoral Innovation (201401006, 201603068), the Department of Shandong Provincial Education (J15LE18), Taishan Scholarship, and Program for New Century Excellent Talents in University.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Gupta S, Kamal R, Mishra S (2016) Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson’s disease. Mol Neurobiol 53:3309–3314CrossRefPubMedGoogle Scholar
  2. 2.
    Li JY, Zhang J, Li NN, Wang L, Lu ZJ, Cheng L et al (2016) Genetic association study between RIT2 and Parkinson’s disease in a Han Chinese population. Neurol Sci 38:343–347CrossRefPubMedGoogle Scholar
  3. 3.
    Bartolomei L, Pastore A, Meligrana L, Sanson E, Bonetto N, Minicuci GM, Marsala SZ, Mesiano T, Bragagnolo L, Antonini A (2018) Relevance of sleep quality on caregiver burden in Parkinson’s disease. Neurol Sci 39:835–839CrossRefPubMedGoogle Scholar
  4. 4.
    Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Ann Neurol 30:365–374CrossRefPubMedGoogle Scholar
  5. 5.
    Gazibara T, Kisic-Tepavcevic D, Svetel M, Tomic A, Stankovic I, Kostic V, Pekmezovic T (2017) Dynamics of change in self-reported disability among persons with Parkinson’s disease after 2 years of follow-up. Neurol Sci 38:1415–1421CrossRefPubMedGoogle Scholar
  6. 6.
    Rush RA, Geffen LB (1980) Dopamine beta-hydroxylase in health and disease. Crit Rev Clin Lab Sci 12:241–277CrossRefPubMedGoogle Scholar
  7. 7.
    Kalayasiri R, Verachai V, Gelernter J, Mutirangura A, Malison RT (2014) Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C-->T in a Thai treatment cohort. Addiction 109:965–976CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lieberman AN, Freedman LS, Goldstein M (1972) Serum dopamine-beta-hydroxylase activity in patients with Huntington’s chorea and Parkinson’s disease. Lancet (London, England) 1:153–154CrossRefGoogle Scholar
  9. 9.
    Hurst JH, LeWitt PA, Burns RS, Foster NL, Lovenberg W (1985) CSF dopamine-beta-hydroxylase activity in Parkinson’s disease. Neurology 35:565–568CrossRefPubMedGoogle Scholar
  10. 10.
    O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-Bourland RE, Madrazo I, Langlais PJ, Robertson D, Biaggioni I (1994) Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson’s disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (London, England : 1979) 86:149–158CrossRefGoogle Scholar
  11. 11.
    Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68:515–522CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zabetian CP, Buxbaum SG, Elston RC, Kohnke MD, Anderson GM, Gelernter J et al (2003) The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Hum Genet 72:1389–1400CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefGoogle Scholar
  14. 14.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chun LS, Samii A, Hutter CM, Griffith A, Roberts JW, Leis BC, Mosley AD, Wander PL, Edwards KL, Payami H, Zabetian CP (2007) DBH-1021C-->T does not modify risk or age at onset in Parkinson’s disease. Ann Neurol 62:99–101CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Healy DG, Abou-Sleiman PM, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Barrone P, Tolosa E, Quinn N, Goldstein DB, Wood NW (2004) A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson’s disease. Ann Neurol 55:443–446CrossRefPubMedGoogle Scholar
  17. 17.
    Ross OA, Heckman MG, Soto AI, Diehl NN, Haugarvoll K, Vilarino-Guell C et al (2008) Dopamine beta-hydroxylase-1021C>T association and Parkinson’s disease. Parkinsonism Relat Disord 14:544–547CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Punia S, Das M, Behari M, Mishra BK, Sahani AK, Govindappa ST et al (2010) Role of polymorphisms in dopamine synthesis and metabolism genes and association of DBH haplotypes with Parkinson’s disease among North Indians. Pharmacogenet Genomics 20:435–441PubMedGoogle Scholar
  19. 19.
    Shao P, Yu YX, Bao JX (2016) Association of dopamine beta-hydroxylase (DBH) polymorphisms with susceptibility to Parkinson’s disease. Med Sci Monit 22:1617–1622CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Li Y, Zhang X, Han X, Guo M, Zou M, Wang L, Li Y, Xiao Y, Zeng W, Song Q (2014) Association between polymorphism of dopamine beta-hydroxylase gene and Parkinson’s disease in Uygurs and Hans of Xinjiang. Zhonghua Yi Xue Za Zhi 94:808–812PubMedGoogle Scholar
  21. 21.
    Zhao XP, Xie HJ, Tang GM, Zhao WW, Xu L, Su JJ, Hao YX, Ren DM (2003) Dopamine beta hydroxylase gene polymorphism and Parkinson’s disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20:238–240PubMedGoogle Scholar
  22. 22.
    Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science (New York, NY) 305:626–629CrossRefGoogle Scholar
  23. 23.
    Snyder C, Mantione K (2014) The effects of morphine on Parkinson’s-related genes PINK1 and PARK2. Med Sci Monit Basic Res 20:63–69CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P et al (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 55:2142–2145CrossRefPubMedGoogle Scholar
  25. 25.
    Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD Jr, Turnbull DM (1991) Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J Neurol Sci 104:203–208CrossRefPubMedGoogle Scholar
  26. 26.
    Mittal S, Bjornevik K (2017) beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. 357:891–898Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders and State Key Disciplines: PhysiologyMedical College of Qingdao UniversityQingdaoChina
  2. 2.Shandong Provincial Collaborative Innovation Center for Neurodegenerative DisordersQingdao UniversityQingdaoChina

Personalised recommendations